Production (Stage)
Akebia Therapeutics, Inc.
AKBA
$2.86
$0.031.06%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 184.91M | 160.18M | 169.88M | 174.50M | 187.23M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 184.91M | 160.18M | 169.88M | 174.50M | 187.23M |
| Cost of Revenue | 31.01M | 25.56M | 26.36M | 30.31M | 30.73M |
| Gross Profit | 153.90M | 134.62M | 143.52M | 144.19M | 156.50M |
| SG&A Expenses | 106.85M | 106.55M | 104.31M | 100.50M | 100.62M |
| Depreciation & Amortization | 27.03M | 36.04M | 36.04M | 36.04M | 36.04M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 202.56M | 205.80M | 202.44M | 207.42M | 220.52M |
| Operating Income | -17.65M | -45.62M | -32.56M | -32.93M | -33.29M |
| Income Before Tax | -45.31M | -69.41M | -45.99M | -40.44M | -43.03M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -45.31 | -69.41 | -45.99 | -40.44 | -43.03 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -45.31M | -69.41M | -45.99M | -40.44M | -43.03M |
| EBIT | -17.65M | -45.62M | -32.56M | -32.93M | -33.29M |
| EBITDA | 10.79M | -8.11M | 5.00M | 4.67M | 4.30M |
| EPS Basic | -0.21 | -0.33 | -0.22 | -0.20 | -0.22 |
| Normalized Basic EPS | -0.12 | -0.19 | -0.13 | -0.12 | -0.13 |
| EPS Diluted | -0.21 | -0.33 | -0.22 | -0.20 | -0.22 |
| Normalized Diluted EPS | -0.12 | -0.19 | -0.13 | -0.12 | -0.13 |
| Average Basic Shares Outstanding | 874.25M | 843.71M | 814.91M | 792.87M | 769.98M |
| Average Diluted Shares Outstanding | 880.36M | 843.71M | 815.51M | 793.46M | 770.58M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |